Catalyst Funds Management Pty Ltd Purchases New Holdings in Invivyd, Inc. $IVVD

Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 37,300 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds and other institutional investors also recently modified their holdings of IVVD. AQR Capital Management LLC increased its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares during the period. XTX Topco Ltd purchased a new position in Invivyd in the 1st quarter valued at $66,000. Invesco Ltd. increased its stake in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after buying an additional 71,485 shares during the period. Nuveen LLC acquired a new position in Invivyd in the 1st quarter valued at $65,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Kevin F. Mclaughlin bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average price of $2.50 per share, with a total value of $125,000.00. Following the purchase, the director owned 50,000 shares of the company’s stock, valued at $125,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 25.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IVVD. D. Boral Capital boosted their price target on shares of Invivyd from $1.00 to $2.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. Cantor Fitzgerald assumed coverage on Invivyd in a research report on Monday, October 6th. They set an “overweight” rating and a $10.00 target price on the stock. HC Wainwright raised their price target on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Invivyd has a consensus rating of “Hold” and a consensus target price of $7.33.

Invivyd Stock Up 4.2%

NASDAQ:IVVD opened at $2.50 on Friday. Invivyd, Inc. has a 52-week low of $0.35 and a 52-week high of $3.07. The stock has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.12. The company has a market capitalization of $582.80 million, a PE ratio of -5.32 and a beta of 0.64.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. The business had revenue of $13.13 million during the quarter, compared to analyst estimates of $12.00 million. As a group, equities analysts anticipate that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.